Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-LILRB4 CAR-T cells

A preparation of autologous T lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a T-cell-receptor (TCR) complex-based chimeric antigen receptor (CAR) specific for two different epitopes of the immune inhibitory receptor leukocyte immunoglobulin-like receptor B member 4 (LILRB4; ILT3; ILT-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, autologous anti-LILRB4 CAR-T cells target and bind to two different epitopes of LILRB4 expressed on tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against LILRB4-expressing tumor cells. LILRB4, a tumor associated antigen (TAA) and an immune inhibitory receptor expressed on immune suppressive myeloid cells, is highly expressed on certain hematologic cancer cells, such as monocytic acute myeloid leukemia (AML) cells. It functions as an immune checkpoint that negatively regulates T-cell activation as its extracellular domain inhibits T-cell activity. It plays an important role in tumor infiltration, T-cell suppression and immune tolerance.
Synonym:autologous anti-ILT3 STAR-T cells
autologous anti-LILRB4 STAR-T cells
autologous anti-LILRB4 synthetic TCR and antigen receptor T cells
LILRB4 STAR-T cells
Search NCI's Drug Dictionary